The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).
 
Nicholas C. Turner
No Relationships to Disclose
 
Melinda L. Telli
Consulting or Advisory Role - AstraZeneca; Vertex
Research Funding - Abbvie (Inst); Biomarin (Inst); Calithera Biosciences (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); PharmaMar (Inst); Sanofi (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Biomarin; Myriad Genetics; PharmaMar
 
Hope S. Rugo
Honoraria - Genomic Health
Speakers' Bureau - Genomic Health
Research Funding - Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Novartis; OBI Pharma; Pfizer; Roche/Genentech
 
Audrey Mailliez
No Relationships to Disclose
 
Johannes Ettl
No Relationships to Disclose
 
Eva-Maria Grischke
No Relationships to Disclose
 
Lida A. Mina
No Relationships to Disclose
 
Judith Balmana Gelpi
No Relationships to Disclose
 
Peter A. Fasching
Honoraria - Amgen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Pfizer; Roche
Research Funding - Amgen; Novartis
 
Sara A. Hurvitz
Research Funding - Amgen (Inst); Bayer (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Dignitana (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medivation (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; OBI Pharma
 
Andrew M. Wardley
Honoraria - AstraZeneca; Lilly; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Roche
Speakers' Bureau - Roche
Research Funding - Roche (Inst)
 
Colombe Chappey
Employment - Medivation
 
Wendy Verret
Employment - Medivation
 
Alison L. Hannah
Leadership - NeoGenomics Laboratories
Stock and Other Ownership Interests - NeoGenomics Laboratories
Consulting or Advisory Role - Basilea; Jazz Pharmaceuticals; Medivation; Nektar
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; McKesson
Research Funding - AbbVie (Inst); AstraZeneca (Inst); Biomarin (Inst); Medivation (Inst); Myriad Genetics (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca